Monopar Therapeutics Inc (MNPR) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Monopar Therapeutics Inc   (NASDAQ: MNPR)


Monopar Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Monopar Therapeutics Inc 's ROA in the second quarter of 2026?
Monopar Therapeutics Inc recorded a cumulative net loss of $-18 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -12.81%.

However, within the Healthcare sector 319 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3285, from total ROA ranking in the first quarter of 2026 at 3889.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 151.13 % 150.1 % 132.97 % 2273.95 % 648.6 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -18 -15 -14 -19 -17
Return On Assets (TTM) -12.81 % -12.59 % -13.95 % -24.83 % -39.52 %
MNPR's Total Ranking # 3285 # 3889 # 3655 # 3936 # 4174
Total Assets (TTM) in million 135 138 140 144 54
Seq. Total Assets Change -2.01 % -1.94 % -2.52 % 168.09 % -2.41 %
Seq. Net Income Change - - - - -

MNPR's 5 Years Annual ROA >> Back to MNPR Management Effectiveness >> Compare MNPR ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 114
Sector # 320
Overall # 3265

Return On Assets Statistics
High Average Low
-12.57 %
-52.33 %
-88.97 %
(Mar 31 2026)   (Jun 30 2024)



  News about Monopar Therapeutics Inc Return on Assets ROA

Monopar Therapeutics: Charting the Course Between Innovation and Financial Struggles

In a time when the biotechnology sector is brimming with promise and potential, Monopar Therapeutics Inc. (Nasdaq: MNPR) stands out as a beacon of hope—and, paradoxically, concern. The clinical-stage company, dedicated to developing groundbreaking treatments for unmet medical needs, recently secured funding through a public offering and private placement while simultaneously grappling with significant financial losses. Announcement of a $40 Million OfferingOn December 20, 2024, Monopar Therapeutics announced the pricing of an underwritten registered offering of 798,655 shares at $23.79 per share, alongside a concurrent private placement of pre-funded warrants. Collectively, these transactions are poised to generate gross proceeds of $40 million for the company, crucial capital that will aid in advancing its innovative projects aimed at critical health challenges.



Financial Statements
Monopar Therapeutics Inc 's Assets $ 135 million MNPR's Balance sheet
Monopar Therapeutics Inc 's Income $ -5 million Quarterly MNPR's Income Statement
MNPR's Income by Division See MNPR's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 132.97 % 720.83 % -44.21 % -35.84 % 22.15 %
Total Assets in million 140 60 7 13 21
Y / Y Net Income Change - - - - -
Net Income in million -14 -16 -8 -11 -9
Annual Return On Assets -9.77 % -25.85 % -114.39 % -79.87 % -44.36 %

MNPR's 5 Years Annual ROA >> Back to MNPR Management Effectiveness >> Compare MNPR ROA to its Competitors



More Return On Assets Ratios
MNPR's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MNPR's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MNPR's Competitors
Subscribers only: Roa for Monopar Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for MNPR's Customers

You may also want to know
MNPR's Roi MNPR's Inventory Turnover Ratio MNPR's Growth Rates MNPR's Dividend Comparisons
MNPR's Profitability Ratios MNPR's Asset Turnover Ratio MNPR's Dividend Growth
MNPR's Roe MNPR's Valuation Ratios MNPR's Financial Strength Ratios MNPR's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA

Date modified: 2026-09-03T16:40:34+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.